Antibiotics: Applications
Antibiotics, also known as antibacterials, are types of medications that destroy or slow down the growth of bacteria. In 1929, Alexander Fleming identified penicillin, the first chemical compound with antibiotic properties. Some of the common antibiotics are Penicillins, Cephalosporins, Carbapenems, Macrolides, Aminoglycosides, Quinolones, Sulfonamides and, Tetracyclines etc. General principles of antibiotic prescribing are use: First-line antibiotics first, Reserve broad spectrum antibiotics for indicated conditions only, prescribe antibiotics for bacterial infections if Symptoms are significant or severe.
The antibiotics market generated sales of US$42 billion in 2009 globally, representing 46% of sales of anti-infective agents (which also include antiviral drugs and vaccines) and 5% of the global pharmaceutical market1. However, the antibiotics market is maturing; it showed an average annual growth of 4% over the past 5 years, compared with a growth of 16.7% and of 16.4% for antiviral drugs and vaccines, respectively.
The cephalosporin class of antibiotics is the largest in terms of sales, generating $11.9 billion in 2009, led by sales of the latest generation of drugs in this class (cefcapene (Flomox; Shionogi), ceftriaxone (Rocephin; Roche) and cefuroxime (Zinnat; GlaxoSmithKline). This class represents 28% of the total antibiotic market, and sales showed a growth of 3.4% over the past 5 years. With sales of $7.9 billion and 19% of the antibiotic market share in 2009, the second largest drug class is the broad-spectrum penicillins, which showed a growth of 5% between 2005 and 2009. The third largest drug class — the fluoroquinolones — had sales of $7.1 billion in 2009, accounting for 17% of the antibiotic market in 2009, and also showed an average growth of 5% between 2005 and 2009. By contrast, as generic versions of an increasing number of macrolides — which had $4.8 billion in sales in 2009 — became available, sales of this class declined by 5% between 2007 and 2009. Overall, the rate of patent expiry of leading antibiotics in the market is set to increase, with several of the current top-selling products facing patent expiry between 2010 and 2016. These include levofloxacin (Levaquin; Johnson & Johnson), moxifloxacin (Avelox; Bayer/Merck) and linezolid (Zyvox; Pfizer), which are expected to lose patent protection in 2011, 2014 and 2016, respectively.
- Antibacterial Agents
- Antifungal Agents
- Penicillin
- Anti-Migraine Agents
- Immunosuppressive agents
Related Conference of Antibiotics: Applications
5th International conference on Vaccines, Vaccination and Immunization
19th International Conference on Allergy and Clinical Immunology
5th International Conference on Immunology And Immunotherapy
Antibiotics: Applications Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibiotics
- Antibiotics used in Industries
- Antibiotics: Advances in Treatment
- Antibiotics: Applications
- Antibiotics: Clinical Trials
- Antibiotics: Infectious Diseases
- Antibiotics: Mechanism of Action
- Antibodies: Infectious Diseases
- Antibodies: Medical Applications
- Antibody Conjugate Therapeutics: Challenge and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Humanization Technologies
- Auto Immune Antibodies
- Bio therapeutics : Early Analytical Development
- Bio Therapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio Therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing(NGS) in Antibody Discovery and Engineering: Overview and Applications
- Protein Engineering and Genetic Engineering
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)